In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133
| Autor: | Christopher C. Rowe, Gareth Jones, John Drago, Daniel Skovronsky, Uwe Ackermann, Hank F. Kung, Rajinder K Dhamija, Svetlana Pejoska, Nobuyuki Okamura, Graeme O'Keefe, Michael Pontecorvo, Julia R. Ellis, Rachel S. Mulligan, Victor L. Villemagne |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Pathology Fluorine Radioisotopes Tetrabenazine Caudate nucleus Striatum Internal medicine Monoaminergic Medicine Humans Radiology Nuclear Medicine and imaging Tissue Distribution Aged Dopamine Plasma Membrane Transport Proteins business.industry Putamen Dopaminergic Brain Parkinson Disease Middle Aged Corpus Striatum Vesicular monoamine transporter Monoamine neurotransmitter Endocrinology Case-Control Studies Positron-Emission Tomography Vesicular Monoamine Transport Proteins Female Caudate Nucleus Radiopharmaceuticals business medicine.drug |
| Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 51(2) |
| ISSN: | 1535-5667 |
| Popis: | PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain. Methods: In this study, a novel 18F-labeled tetrabenazine derivative, 18F-(+)fluoropropyldihydrotetrabenazine (18F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) of 18F-AV-133 was calculated using Logan graphical analysis. Voxel-based and volume-of-interest–based analyses of BP images were performed to examine brain regional reductions in VMAT2 density in PD. Results: VMAT2 BP was decreased by 81% in the posterior putamen, 70% in the anterior putamen, and 48% in the caudate nucleus of PD patients. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of PD patients. Furthermore, VMAT2 BPs in the caudate nuclei significantly correlated with the clinical severity of PD. Conclusion: These findings indicate that the novel 18F-labeled ligand 18F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with 18F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|